Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4817 Comments
1656 Likes
1
Heer
Power User
2 hours ago
Who else is trying to keep up with this trend?
👍 224
Reply
2
Dayshun
Community Member
5 hours ago
Access real-time US stock market data with expert analysis and strategic recommendations focused on building a balanced portfolio. We provide free stock screening, fundamental research, sector analysis, and investment education through articles and tutorials. Our platform delivers comprehensive market coverage with real-time alerts to support your investment decisions. Experience professional-grade tools and personalized guidance for long-term growth with our beginner-friendly interface and advanced features.
👍 77
Reply
3
Kashandra
Returning User
1 day ago
This feels like a secret but no one told me.
👍 112
Reply
4
Delores
Active Contributor
1 day ago
Am I the only one seeing this?
👍 88
Reply
5
Nimrat
Returning User
2 days ago
Balanced approach, easy to digest key information.
👍 236
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.